25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Hinova Pharmaceuticals Inc. A
Buy, Hold or Sell?

Let's analyze Hinova Pharmaceuticals Inc. A together

I guess you are interested in Hinova Pharmaceuticals Inc. A. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hinova Pharmaceuticals Inc. A. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Hinova Pharmaceuticals Inc. A

I send you an email if I find something interesting about Hinova Pharmaceuticals Inc. A.

1. Quick Overview

1.1. Quick analysis of Hinova Pharmaceuticals Inc. A (30 sec.)










1.2. What can you expect buying and holding a share of Hinova Pharmaceuticals Inc. A? (30 sec.)

How much money do you get?

How much money do you get?
¥0.00
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥12.44
Expected worth in 1 year
¥10.70
How sure are you?
18.2%

+ What do you gain per year?

Total Gains per Share
¥-1.74
Return On Investment
-5.2%

For what price can you sell your share?

Current Price per Share
¥33.61
Expected price per share
¥28.17 - ¥41.59
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Hinova Pharmaceuticals Inc. A (5 min.)




Live pricePrice per Share (EOD)
¥33.61

2.2. Growth of Hinova Pharmaceuticals Inc. A (5 min.)




Is Hinova Pharmaceuticals Inc. A growing?

Current yearPrevious yearGrowGrow %
How rich?$169m$205.1m-$26.5m-14.9%

How much money is Hinova Pharmaceuticals Inc. A making?

Current yearPrevious yearGrowGrow %
Making money-$7.2m-$10.8m$3.6m50.8%
Net Profit Margin-12,119.5%-1,196.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Hinova Pharmaceuticals Inc. A (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Hinova Pharmaceuticals Inc. A?

Welcome investor! Hinova Pharmaceuticals Inc. A's management wants to use your money to grow the business. In return you get a share of Hinova Pharmaceuticals Inc. A.

First you should know what it really means to hold a share of Hinova Pharmaceuticals Inc. A. And how you can make/lose money.

Speculation

The Price per Share of Hinova Pharmaceuticals Inc. A is ¥33.61. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Hinova Pharmaceuticals Inc. A.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Hinova Pharmaceuticals Inc. A, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥12.44. Based on the TTM, the Book Value Change Per Share is ¥-0.44 per quarter. Based on the YOY, the Book Value Change Per Share is ¥-0.59 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Hinova Pharmaceuticals Inc. A.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps-0.07-0.2%-0.07-0.2%-0.11-0.3%-0.09-0.3%-0.09-0.3%
Usd Book Value Change Per Share-0.07-0.2%-0.06-0.2%-0.08-0.2%0.160.5%0.160.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.07-0.2%-0.06-0.2%-0.08-0.2%0.160.5%0.160.5%
Usd Price Per Share4.93-4.89-6.58-5.12-5.12-
Price to Earnings Ratio-16.56--16.66--15.01--14.11--14.11-
Price-to-Total Gains Ratio-74.93--84.99--82.67--72.68--72.68-
Price to Book Ratio2.89-2.70-3.18-2.55-2.55-
Price-to-Total Gains Ratio-74.93--84.99--82.67--72.68--72.68-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.614653
Number of shares216
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.060.16
Usd Total Gains Per Share-0.060.16
Gains per Quarter (216 shares)-12.8733.70
Gains per Year (216 shares)-51.46134.78
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-52-611134125
20-103-1121268260
31-155-1632402395
41-207-2143537530
51-258-2653671665
61-310-3164805800
72-362-3675939935
82-413-418510731070
92-465-469612071205
102-517-520613411340

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.011.00.00.0%0.011.00.00.0%0.011.00.00.0%0.011.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.09.00.018.2%2.09.00.018.2%2.09.00.018.2%2.09.00.018.2%
Dividend per Share4.00.00.0100.0%11.00.00.0100.0%11.00.00.0100.0%11.00.00.0100.0%11.00.00.0100.0%
Total Gains per Share0.04.00.00.0%2.09.00.018.2%2.09.00.018.2%2.09.00.018.2%2.09.00.018.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Hinova Pharmaceuticals Inc. A compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.480-0.436-9%-0.587+22%1.131-142%1.131-142%
Book Value Per Share--12.43813.139-5%15.093-18%13.990-11%13.990-11%
Current Ratio--6.3769.038-29%9.889-36%9.441-32%9.441-32%
Debt To Asset Ratio--0.1230.099+24%0.099+25%0.106+16%0.106+16%
Debt To Equity Ratio--0.1410.111+27%0.110+28%0.121+17%0.121+17%
Dividend Per Share--0.0010.002-36%0.006-78%0.005-78%0.005-78%
Enterprise Value--3381494246.8703380710902.963+0%4580447256.233-26%3907094366.483-13%3907094366.483-13%
Eps---0.542-0.531-2%-0.800+48%-0.688+27%-0.688+27%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.727-0.825+13%-1.099+51%-0.908+25%-0.908+25%
Free Cash Flow To Equity Per Share---0.727-0.825+13%-1.099+51%-0.908+25%-0.908+25%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap3327914316.000-7%3554660040.0003523717665.000+1%4743589857.000-25%3691391582.182-4%3691391582.182-4%
Net Profit Margin----121.1950%-11.9620%-48.4210%-48.4210%
Operating Margin----0%-0%-0%-0%
Operating Ratio---134.821-100%13.341-100%53.877-100%53.877-100%
Pb Ratio2.702-7%2.8862.696+7%3.184-9%2.549+13%2.549+13%
Pe Ratio-15.505+6%-16.561-16.663+1%-15.007-9%-14.111-15%-14.111-15%
Price Per Share33.610-7%35.90035.588+1%47.908-25%37.281-4%37.281-4%
Price To Free Cash Flow Ratio-11.552+6%-12.339-11.066-10%-11.752-5%-10.783-13%-10.783-13%
Price To Total Gains Ratio-70.146+6%-74.925-84.990+13%-82.674+10%-72.677-3%-72.677-3%
Quick Ratio--2.8074.191-33%3.505-20%3.837-27%3.837-27%
Return On Assets---0.038-0.036-5%-0.048+25%-0.046+20%-0.046+20%
Return On Equity---0.044-0.040-7%-0.053+22%-0.052+20%-0.052+20%
Total Gains Per Share---0.479-0.434-9%-0.582+21%1.136-142%1.136-142%
Usd Book Value--169094867.195178623855.169-5%205183385.926-18%190188382.622-11%190188382.622-11%
Usd Book Value Change Per Share---0.066-0.060-9%-0.081+22%0.155-142%0.155-142%
Usd Book Value Per Share--1.7081.804-5%2.072-18%1.921-11%1.921-11%
Usd Dividend Per Share--0.0000.000-36%0.001-78%0.001-78%0.001-78%
Usd Enterprise Value--464279160.095464171606.977+0%628895408.281-26%536444056.518-13%536444056.518-13%
Usd Eps---0.074-0.073-2%-0.110+48%-0.095+27%-0.095+27%
Usd Free Cash Flow---9888549.961-11218853.419+13%-14938614.725+51%-12341097.826+25%-12341097.826+25%
Usd Free Cash Flow Per Share---0.100-0.113+13%-0.151+51%-0.125+25%-0.125+25%
Usd Free Cash Flow To Equity Per Share---0.100-0.113+13%-0.151+51%-0.125+25%-0.125+25%
Usd Market Cap456922635.587-7%488054823.492483806435.405+1%651294887.366-25%506828064.234-4%506828064.234-4%
Usd Price Per Share4.615-7%4.9294.886+1%6.578-25%5.119-4%5.119-4%
Usd Profit---7367433.810-7214573.239-2%-10882085.959+48%-9358176.843+27%-9358176.843+27%
Usd Revenue---3766.637-100%56664.479-100%21974.951-100%21974.951-100%
Usd Total Gains Per Share---0.066-0.060-9%-0.080+21%0.156-142%0.156-142%
 EOD+3 -5MRQTTM+13 -22YOY+20 -155Y+14 -2110Y+14 -21

3.3 Fundamental Score

Let's check the fundamental score of Hinova Pharmaceuticals Inc. A based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-15.505
Price to Book Ratio (EOD)Between0-12.702
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.807
Current Ratio (MRQ)Greater than16.376
Debt to Asset Ratio (MRQ)Less than10.123
Debt to Equity Ratio (MRQ)Less than10.141
Return on Equity (MRQ)Greater than0.15-0.044
Return on Assets (MRQ)Greater than0.05-0.038
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Hinova Pharmaceuticals Inc. A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.642
Ma 20Greater thanMa 5031.957
Ma 50Greater thanMa 10030.690
Ma 100Greater thanMa 20033.457
OpenGreater thanClose33.040
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Hinova Pharmaceuticals Inc. A

Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company's products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501, a product in phase II clinical trials for the treatment of hyperuricemia and gout; HP558, a product in phase II clinical trials to treat various late-stage cancers; and HP518, an oral PROTAC drug in phase I clinical trials with a focus on to solve the drug resistance of AR-mutated prostate cancer. Hinova Pharmaceuticals Inc. was founded in 2013 and is headquartered in Chengdu, China.

Fundamental data was last updated by Penke on 2025-02-23 12:01:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Hinova Pharmaceuticals Inc. A earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Hinova Pharmaceuticals Inc. A to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that ¥0.00 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hinova Pharmaceuticals Inc. A:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-12,119.5%+12,119.5%
TTM-12,119.5%YOY-1,196.2%-10,923.4%
TTM-12,119.5%5Y-4,842.1%-7,277.5%
5Y-4,842.1%10Y-4,842.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--101.0%+101.0%
TTM-12,119.5%-203.6%-11,915.9%
YOY-1,196.2%-199.0%-997.2%
5Y-4,842.1%-333.8%-4,508.3%
10Y-4,842.1%-481.5%-4,360.6%
4.3.1.2. Return on Assets

Shows how efficient Hinova Pharmaceuticals Inc. A is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Hinova Pharmaceuticals Inc. A to the Biotechnology industry mean.
  • -3.8% Return on Assets means that Hinova Pharmaceuticals Inc. A generated ¥-0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hinova Pharmaceuticals Inc. A:

  • The MRQ is -3.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.8%TTM-3.6%-0.2%
TTM-3.6%YOY-4.8%+1.1%
TTM-3.6%5Y-4.6%+1.0%
5Y-4.6%10Y-4.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.8%-12.4%+8.6%
TTM-3.6%-12.4%+8.8%
YOY-4.8%-11.8%+7.0%
5Y-4.6%-13.2%+8.6%
10Y-4.6%-15.2%+10.6%
4.3.1.3. Return on Equity

Shows how efficient Hinova Pharmaceuticals Inc. A is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Hinova Pharmaceuticals Inc. A to the Biotechnology industry mean.
  • -4.4% Return on Equity means Hinova Pharmaceuticals Inc. A generated ¥-0.04 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hinova Pharmaceuticals Inc. A:

  • The MRQ is -4.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.4%TTM-4.0%-0.3%
TTM-4.0%YOY-5.3%+1.3%
TTM-4.0%5Y-5.2%+1.2%
5Y-5.2%10Y-5.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.4%-15.9%+11.5%
TTM-4.0%-16.6%+12.6%
YOY-5.3%-15.2%+9.9%
5Y-5.2%-19.0%+13.8%
10Y-5.2%-20.5%+15.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Hinova Pharmaceuticals Inc. A.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Hinova Pharmaceuticals Inc. A is operating .

  • Measures how much profit Hinova Pharmaceuticals Inc. A makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Hinova Pharmaceuticals Inc. A to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hinova Pharmaceuticals Inc. A:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.6%+204.6%
TTM--316.3%+316.3%
YOY--208.2%+208.2%
5Y--367.6%+367.6%
10Y--483.9%+483.9%
4.3.2.2. Operating Ratio

Measures how efficient Hinova Pharmaceuticals Inc. A is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are ¥0.00 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Hinova Pharmaceuticals Inc. A:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM134.821-134.821
TTM134.821YOY13.341+121.480
TTM134.8215Y53.877+80.944
5Y53.87710Y53.8770.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.167-2.167
TTM134.8213.118+131.703
YOY13.3413.194+10.147
5Y53.8774.689+49.188
10Y53.8776.422+47.455
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Hinova Pharmaceuticals Inc. A.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Hinova Pharmaceuticals Inc. A is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.38 means the company has ¥6.38 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Hinova Pharmaceuticals Inc. A:

  • The MRQ is 6.376. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.038. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.376TTM9.038-2.662
TTM9.038YOY9.889-0.851
TTM9.0385Y9.441-0.403
5Y9.44110Y9.4410.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.3763.586+2.790
TTM9.0383.854+5.184
YOY9.8894.496+5.393
5Y9.4415.971+3.470
10Y9.4416.269+3.172
4.4.3.2. Quick Ratio

Measures if Hinova Pharmaceuticals Inc. A is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Hinova Pharmaceuticals Inc. A to the Biotechnology industry mean.
  • A Quick Ratio of 2.81 means the company can pay off ¥2.81 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hinova Pharmaceuticals Inc. A:

  • The MRQ is 2.807. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.191. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.807TTM4.191-1.384
TTM4.191YOY3.505+0.686
TTM4.1915Y3.837+0.355
5Y3.83710Y3.8370.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8073.068-0.261
TTM4.1913.312+0.879
YOY3.5054.393-0.888
5Y3.8375.972-2.135
10Y3.8376.490-2.653
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Hinova Pharmaceuticals Inc. A.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Hinova Pharmaceuticals Inc. A assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Hinova Pharmaceuticals Inc. A to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that Hinova Pharmaceuticals Inc. A assets are financed with 12.3% credit (debt) and the remaining percentage (100% - 12.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hinova Pharmaceuticals Inc. A:

  • The MRQ is 0.123. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.099. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.123TTM0.099+0.024
TTM0.099YOY0.099+0.001
TTM0.0995Y0.106-0.007
5Y0.10610Y0.1060.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1230.340-0.217
TTM0.0990.341-0.242
YOY0.0990.310-0.211
5Y0.1060.363-0.257
10Y0.1060.384-0.278
4.5.4.2. Debt to Equity Ratio

Measures if Hinova Pharmaceuticals Inc. A is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Hinova Pharmaceuticals Inc. A to the Biotechnology industry mean.
  • A Debt to Equity ratio of 14.1% means that company has ¥0.14 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hinova Pharmaceuticals Inc. A:

  • The MRQ is 0.141. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.111. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.141TTM0.111+0.030
TTM0.111YOY0.110+0.001
TTM0.1115Y0.121-0.010
5Y0.12110Y0.1210.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1410.387-0.246
TTM0.1110.428-0.317
YOY0.1100.391-0.281
5Y0.1210.451-0.330
10Y0.1210.495-0.374
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Hinova Pharmaceuticals Inc. A generates.

  • Above 15 is considered overpriced but always compare Hinova Pharmaceuticals Inc. A to the Biotechnology industry mean.
  • A PE ratio of -16.56 means the investor is paying ¥-16.56 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hinova Pharmaceuticals Inc. A:

  • The EOD is -15.505. Based on the earnings, the company is expensive. -2
  • The MRQ is -16.561. Based on the earnings, the company is expensive. -2
  • The TTM is -16.663. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-15.505MRQ-16.561+1.056
MRQ-16.561TTM-16.663+0.102
TTM-16.663YOY-15.007-1.657
TTM-16.6635Y-14.111-2.552
5Y-14.11110Y-14.1110.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-15.505-2.221-13.284
MRQ-16.561-2.782-13.779
TTM-16.663-3.254-13.409
YOY-15.007-3.403-11.604
5Y-14.111-6.225-7.886
10Y-14.111-6.819-7.292
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hinova Pharmaceuticals Inc. A:

  • The EOD is -11.552. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -12.339. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -11.066. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.552MRQ-12.339+0.787
MRQ-12.339TTM-11.066-1.273
TTM-11.066YOY-11.752+0.687
TTM-11.0665Y-10.783-0.283
5Y-10.78310Y-10.7830.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.552-3.007-8.545
MRQ-12.339-3.693-8.646
TTM-11.066-3.891-7.175
YOY-11.752-4.438-7.314
5Y-10.783-8.306-2.477
10Y-10.783-9.274-1.509
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Hinova Pharmaceuticals Inc. A is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.89 means the investor is paying ¥2.89 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Hinova Pharmaceuticals Inc. A:

  • The EOD is 2.702. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.886. Based on the equity, the company is underpriced. +1
  • The TTM is 2.696. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.702MRQ2.886-0.184
MRQ2.886TTM2.696+0.191
TTM2.696YOY3.184-0.488
TTM2.6965Y2.549+0.147
5Y2.54910Y2.5490.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.7021.910+0.792
MRQ2.8862.190+0.696
TTM2.6962.397+0.299
YOY3.1842.465+0.719
5Y2.5493.815-1.266
10Y2.5494.512-1.963
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets1,404,738
Total Liabilities173,166
Total Stockholder Equity1,231,572
 As reported
Total Liabilities 173,166
Total Stockholder Equity+ 1,231,572
Total Assets = 1,404,738

Assets

Total Assets1,404,738
Total Current Assets956,760
Long-term Assets447,978
Total Current Assets
Cash And Cash Equivalents 488,047
Short-term Investments 421,244
Inventory 165
Other Current Assets 27,745
Total Current Assets  (as reported)956,760
Total Current Assets  (calculated)937,202
+/- 19,558
Long-term Assets
Property Plant Equipment 302,490
Intangible Assets 30,723
Long-term Assets Other 107,722
Long-term Assets  (as reported)447,978
Long-term Assets  (calculated)440,936
+/- 7,043

Liabilities & Shareholders' Equity

Total Current Liabilities150,050
Long-term Liabilities23,115
Total Stockholder Equity1,231,572
Total Current Liabilities
Accounts payable 134,277
Total Current Liabilities  (as reported)150,050
Total Current Liabilities  (calculated)134,277
+/- 15,774
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt6,565
Long-term Liabilities  (as reported)23,115
Long-term Liabilities  (calculated)6,565
+/- 16,550
Total Stockholder Equity
Total Stockholder Equity (as reported)1,231,572
Total Stockholder Equity (calculated)0
+/- 1,231,572
Other
Capital Stock99,016
Common Stock Shares Outstanding 99,016
Net Invested Capital 1,231,572
Net Working Capital 806,710
Property Plant and Equipment Gross 302,490



6.2. Balance Sheets Structured

Currency in CNY. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-31
> Total Assets 
918,570
1,835,984
1,799,739
1,735,074
1,690,252
1,629,184
1,575,726
1,491,565
1,434,439
1,445,184
1,404,738
1,404,7381,445,1841,434,4391,491,5651,575,7261,629,1841,690,2521,735,0741,799,7391,835,984918,570
   > Total Current Assets 
867,693
1,782,458
1,731,819
1,611,310
1,536,651
1,342,548
1,265,784
1,147,226
1,071,353
1,022,993
956,760
956,7601,022,9931,071,3531,147,2261,265,7841,342,5481,536,6511,611,3101,731,8191,782,458867,693
       Cash And Cash Equivalents 
811,403
1,388,705
275,609
1,201,610
790,796
780,695
738,538
813,227
283,459
533,441
488,047
488,047533,441283,459813,227738,538780,695790,7961,201,610275,6091,388,705811,403
       Short-term Investments 
0
351,546
1,421,482
366,241
696,200
517,258
470,371
290,622
736,293
440,939
421,244
421,244440,939736,293290,622470,371517,258696,200366,2411,421,482351,5460
       Inventory 
5
4
5
6
4
5
4
6
5
147
165
165147564546545
       Other Current Assets 
26,564
14,236
16,488
17,080
20,264
14,346
17,978
11,934
17,082
23,763
27,745
27,74523,76317,08211,93417,97814,34620,26417,08016,48814,23626,564
   > Long-term Assets 
50,876
53,526
67,920
123,764
153,601
286,637
309,942
344,339
363,086
422,192
447,978
447,978422,192363,086344,339309,942286,637153,601123,76467,92053,52650,876
       Property Plant Equipment 
0
0
0
0
116,639
138,673
156,629
187,990
215,706
279,415
302,490
302,490279,415215,706187,990156,629138,673116,6390000
       Intangible Assets 
32,400
32,184
32,021
31,859
31,697
31,535
31,372
31,210
31,048
30,885
30,723
30,72330,88531,04831,21031,37231,53531,69731,85932,02132,18432,400
       Long-term Assets Other 
1,494
764
633
209
192
111,367
116,889
118,066
109,270
104,838
107,722
107,722104,838109,270118,066116,889111,3671922096337641,494
> Total Liabilities 
188,858
146,816
162,950
149,683
161,105
170,192
171,591
124,475
108,336
166,050
173,166
173,166166,050108,336124,475171,591170,192161,105149,683162,950146,816188,858
   > Total Current Liabilities 
183,874
142,304
158,882
138,271
141,839
151,817
153,888
106,845
90,576
141,861
150,050
150,050141,86190,576106,845153,888151,817141,839138,271158,882142,304183,874
       Short Long Term Debt 
95,153
67,439
68,110
32,446
34,115
34,309
30,000
3,768
3,758
3,569
0
03,5693,7583,76830,00034,30934,11532,44668,11067,43995,153
       Accounts payable 
80,911
64,239
75,727
89,960
97,732
103,210
107,067
92,868
77,597
126,586
134,277
134,277126,58677,59792,868107,067103,21097,73289,96075,72764,23980,911
   > Long-term Liabilities 
4,985
4,512
4,068
11,411
19,266
18,375
17,703
17,630
17,760
24,190
23,115
23,11524,19017,76017,63017,70318,37519,26611,4114,0684,5124,985
       Capital Lease Obligations Min Short Term Debt
4,122
3,937
3,681
3,311
11,166
10,275
9,603
9,080
9,210
7,640
6,565
6,5657,6409,2109,0809,60310,27511,1663,3113,6813,9374,122
> Total Stockholder Equity
729,711
1,689,168
1,636,788
1,585,392
1,529,147
1,458,993
1,404,135
1,367,090
1,326,103
1,279,134
1,231,572
1,231,5721,279,1341,326,1031,367,0901,404,1351,458,9931,529,1471,585,3921,636,7881,689,168729,711
   Common Stock00000000000
   Retained Earnings Total Equity00000000000
   Accumulated Other Comprehensive Income 00000000000
   Capital Surplus 00000000000
   Treasury Stock00000000000
   Other Stockholders Equity 00000000000



6.3. Balance Sheets

Currency in CNY. All numbers in thousands.




6.4. Cash Flows

Currency in CNY. All numbers in thousands.




6.5. Income Statements

Currency in CNY. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in CNY. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-330,643
Operating Income-330,643-330,643
 
Operating Expense (+$)
Research Development248,268
Selling General Administrative65,560
Selling And Marketing Expenses0
Operating Expense330,643313,828
 
Net Interest Income (+$)
Interest Income12,139
Interest Expense-1,488
Other Finance Cost-60
Net Interest Income10,591
 
Pretax Income (+$)
Operating Income-330,643
Net Interest Income10,591
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-294,139-330,643
EBIT - interestExpense = -1,488
-294,158
-292,671
Interest Expense1,488
Earnings Before Interest and Taxes (EBIT)0-292,652
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-294,139
Tax Provision-19
Net Income From Continuing Ops-294,158-294,158
Net Income-294,158
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-10,591
 

Technical Analysis of Hinova Pharmaceuticals Inc. A
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Hinova Pharmaceuticals Inc. A. The general trend of Hinova Pharmaceuticals Inc. A is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Hinova Pharmaceuticals Inc. A's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hinova Pharmaceuticals Inc. A.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 37.53 < 40.51 < 41.59.

The bearish price targets are: 32.00 > 30.24 > 28.17.

Tweet this
Hinova Pharmaceuticals Inc. A Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hinova Pharmaceuticals Inc. A. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hinova Pharmaceuticals Inc. A Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hinova Pharmaceuticals Inc. A. The current macd is 1.13815038.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Hinova Pharmaceuticals Inc. A price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Hinova Pharmaceuticals Inc. A. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Hinova Pharmaceuticals Inc. A price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Hinova Pharmaceuticals Inc. A Daily Moving Average Convergence/Divergence (MACD) ChartHinova Pharmaceuticals Inc. A Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hinova Pharmaceuticals Inc. A. The current adx is 41.52.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Hinova Pharmaceuticals Inc. A shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Hinova Pharmaceuticals Inc. A Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hinova Pharmaceuticals Inc. A. The current sar is 35.90.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Hinova Pharmaceuticals Inc. A Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hinova Pharmaceuticals Inc. A. The current rsi is 58.64. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Hinova Pharmaceuticals Inc. A Daily Relative Strength Index (RSI) ChartHinova Pharmaceuticals Inc. A Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hinova Pharmaceuticals Inc. A. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Hinova Pharmaceuticals Inc. A price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Hinova Pharmaceuticals Inc. A Daily Stochastic Oscillator ChartHinova Pharmaceuticals Inc. A Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hinova Pharmaceuticals Inc. A. The current cci is 63.22.

Hinova Pharmaceuticals Inc. A Daily Commodity Channel Index (CCI) ChartHinova Pharmaceuticals Inc. A Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hinova Pharmaceuticals Inc. A. The current cmo is 15.55.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Hinova Pharmaceuticals Inc. A Daily Chande Momentum Oscillator (CMO) ChartHinova Pharmaceuticals Inc. A Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hinova Pharmaceuticals Inc. A. The current willr is -37.72652389.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Hinova Pharmaceuticals Inc. A is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Hinova Pharmaceuticals Inc. A Daily Williams %R ChartHinova Pharmaceuticals Inc. A Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hinova Pharmaceuticals Inc. A.

Hinova Pharmaceuticals Inc. A Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hinova Pharmaceuticals Inc. A. The current atr is 1.5347028.

Hinova Pharmaceuticals Inc. A Daily Average True Range (ATR) ChartHinova Pharmaceuticals Inc. A Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hinova Pharmaceuticals Inc. A. The current obv is 5,913,091.

Hinova Pharmaceuticals Inc. A Daily On-Balance Volume (OBV) ChartHinova Pharmaceuticals Inc. A Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hinova Pharmaceuticals Inc. A. The current mfi is 71.63.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Hinova Pharmaceuticals Inc. A Daily Money Flow Index (MFI) ChartHinova Pharmaceuticals Inc. A Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hinova Pharmaceuticals Inc. A.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-09-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-10-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-12-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-24MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-28ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside

6.3. Candlestick Patterns

Hinova Pharmaceuticals Inc. A Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hinova Pharmaceuticals Inc. A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.642
Ma 20Greater thanMa 5031.957
Ma 50Greater thanMa 10030.690
Ma 100Greater thanMa 20033.457
OpenGreater thanClose33.040
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Hinova Pharmaceuticals Inc. A with someone you think should read this too:
  • Are you bullish or bearish on Hinova Pharmaceuticals Inc. A? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Hinova Pharmaceuticals Inc. A? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hinova Pharmaceuticals Inc. A

I send you an email if I find something interesting about Hinova Pharmaceuticals Inc. A.


Comments

How you think about this?

Leave a comment

Stay informed about Hinova Pharmaceuticals Inc. A.

Receive notifications about Hinova Pharmaceuticals Inc. A in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.